RGD-TRAIL抗肿瘤作用的细胞筛选研究  

Cell screening for evaluating anti-tumor effect of RGD-TRAIL

作　　者：韦利军 于泉 刘军 

机构地区：[1]常州千红生化制药股份有限公司,常州213022

出　　处：《中国新药杂志》2015年第9期1065-1068,1073,共5页Chinese Journal of New Drugs

基　　金：国家"重大新药创制"科技重大专项(2009ZX09103-675;2012ZX09401012);常州市科技支撑计划(社会发展)(CE20115044)

摘　　要：目的:通过体外细胞实验,来确定对RGD-TRAIL的敏感肿瘤细胞株,为体内试验提供参考。方法:利用靶向抗肿瘤蛋白RGD-TRAIL处理30株人肿瘤细胞系72 h后,通过CTG方法测定药物在各个肿瘤细胞系中的细胞增殖50%抑制浓度(IC50),来确定对RGD-TRAIL的敏感肿瘤细胞株。结果:在所有测试的肿瘤细胞系中,对RGD-TRAIL最为敏感的是COLO 205,A-673和NCI-H358,它们的IC50皆小于0.05μg·m L-1;其次MDA-MB-231和Calu-3对RGD-TRAIL也较敏感,IC50值分别为0.3和1.9μg·m L-1;其余细胞系对RGD-TRAIL的IC50值均大于40μg·m L-1。结论:对RGD-TRAIL敏感的肿瘤细胞株为COLO 205(结肠癌)、A-673(骨癌)和NCI-H358(非小细胞肺癌)。Objective： To find cancer cell lines sensitive to RGD-TRAIL, a recombinant cancer-targeting anti-tumor protein drug, in vitro for providing a reference to in vivo experiments. Methods： Thirty human cancer cell lines were selected, and treated with RGD-TRAIL for 72 hours. Then, CellTiter-Glo （CTG） was used to deter- mine IC50 of RGD-TRAIL in different cancer cell lines to confirm the sensitive cell lines. Results ： Of all the 30 hu- man cancer cell lines, the most sensitive ones were COLO 205, A-673 and NCI-H358 cells, in which ICs0 was less than 0.05 p,μmL-1. MDA-MB-231 and Calu-3 cells were also sensitive to RGD-TRAIL with ICso of 0.3 and 1.9 μg·mL- 1 , respectively. IC50 values of the other 25 human cancer cell lines were greater than 40 μg·mL- 1 Con- clusion： Cancer cell lines sensitive to RGD-TRAIL are COLO 205 （large intestine） , A-673 （bone） and NCI-H358 cells （lung）.

关 键 词：RGD-TRAIL 抗肿瘤 细胞筛选 

分 类 号：R965[医药卫生—药理学]